Laboratory assessment of familial, nonthrombocytopenic mucocutaneous bleeding: A definitive diagnosis is often not possible

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 7, 2008, Pages 654-662

  Pereira, Jaime ^a   Quiroga, Teresa ^a   Mezzano, Diego ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Disorders of primary hemostasis; Laboratory diagnosis; Mucocutaneous bleeding; Platelet function testing

Indexed keywords

ACETYLSALICYLIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOCYTE FACTOR 3;

BERNARD SOULIER DISEASE; BLEEDING DISORDER; BLEEDING TIME; BLOOD CLOTTING DISORDER; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FAMILIAL DISEASE; FIBRINOLYSIS; GLANZMANN DISEASE; HUMAN; LABORATORY DIAGNOSIS; MEDICAL DECISION MAKING; MENORRHAGIA; MUCOCUTANEOUS BLEEDING; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; BLOOD PROTEINS; HEMORRHAGE; HUMANS; PLATELET FUNCTION TESTS; SKIN DISEASES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 58149091910     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1104544     Document Type: Review

References (77)

1. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003;101:2089-2093
2. Friberg B, Orno AK, Lindgren A, Lethagen S. Bleeding disorders among young women: a population-based prevalence study. Acta Obstet Gynecol Scand 2006;85:200-206
3. Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, et al. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988;59:349-352
4. Nosek-Cenkowska B, Cheang MS, Pizzi NJ, Israels ED, Gerrard JM. Bleeding/bruising symptomatology in children with and without bleeding disorders. Thromb Haemost 1991;65:237-241
5. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005;3:2619-2626
6. Quiroga T, Goycoolea M, Panes O, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007;92:357-365
7. Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev 2007;21:89-97
8. McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004;104:159-165
9. Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995;155:1409-1415
10. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds - a clinical and laboratory study. Thromb Haemost 1995;73:194-202
11. Montgomery RR. von Willebrand disease - the relevance of history. J Thromb Haemost 2005;3:2617-2618
12. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006;4:766-773
13. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351:485-489
14. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001;97:630-636
15. Saxena R, Gupta M, Gupta PK, et al. Inherited bleeding disorders in Indian women with menorrhagia. Haemophilia 2003;9:193-196
16. Philipp CS, Dilley A, Miller CH, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003;1:477-484
17. Shankar M, Chi C, Kadir RA. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008;14:15-20
18. Mikhail S, Varadarajan R, Kouides P. The prevalence of disorders of haemostasis in adolescents with menorrhagia referred to a haemophilia treatment centre. Haemophilia 2007;13:627-632
19. Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 2007;5(Suppl 1):157-166
20. Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia 2008;14:415-422
21. Favaloro EJ. Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis? Haematologica 2007;92:292-296
22. Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989;113:1219-1224
23. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20
24. Lind SE. The bleeding time does not predict clinical bleeding. Blood 1991;77:2547-2552
25. Triplett DA. The bleeding time. Neither pariah or panacea. Arch Pathol Lab Med 1989;113:1207-1208
26. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331
27. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35-39
28. Dean JA, Blanchette VS, Carcao MD, et al. Von Willebrand disease in a pediatric-based population - Comparison of type 1 diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen binding assay. Thromb Haemost 2000;84:401-409
29. Schlammadinger A, Kerényi A, Muszbek L, Boda Z. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease. Thromb Haemost 2000;84:88-92
30. Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180-189
31. Favaloro EJ. Clinical application of the PFA-100®. Curr Opin Hematol 2002;9:407-415
32. Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100® system in patients with congenital defects of platelet secretion. Thromb Res 1999;96:213-217
33. Kerényi A, Schlammadinger A, Ajzner E, et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999;96:487-492
34. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003;1:1628-1636
35. Rao AK. Inherited defects in platelet signalling mechanisms. J Thromb Haemost 2003;1:671-681
36. â in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319
37. Quiroga T, Goycoolea M, Muñoz B, et al. Template bleeding time and PFA-1001 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004;2:892-898
38. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100® testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007;5:2393-2398
39. Acharya SS, Coughlin A, Dimichele DMand the North American Rare Bleeding Disorder Study Group. Rare bleeding disorder registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemia. J Thromb Haemost 2004;2:248-256
40. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002;8:308-321
41. Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, et al. Bleeding in carriers of haemophilia. Blood 2006;108:52-56
42. Konkle BA. Clinical approach to the bleeding patient. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis. Basic Principles & Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1147-1158
43. Gomez K, Bolton-Maggs P. Factor XI-deficiency. Haemophilia 2008:27 [Epub ahead of print]
44. Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001;98:257-265
45. Griffin GC, Mammen EF, Sokol RJ, Perrotta AL, Stoyanovich A, Abilgaard CF. Alpha 2-antiplasmin deficiency. An overlooked cause of hemorrhage. Am J Pediatr Hematol Oncol 1993;15:328-330
46. Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EK. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991;77:528-532
47. Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993;81:2357-2362
48. Takahashi Y, Tanaka T, Minowa H, et al. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency. Int J Hematol 1996;64:61-68
49. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997;90:204-208
50. Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006;32:456-471
51. Favaloro EJ, Bonar B, Kershaw G, et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program. Semin Thromb Hemost 2006;32:505-513
52. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus "variants". Blood 1980;56:712-716
53. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. Von Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004;111:734-740
54. Quiroga T, Pérez M, Rodr?́guez S, et al. Skin and mucous membrane hemorrhages. Clinical assessment and relative frequency of hereditary diseases in the Chilean population. Rev Med Chil 1997;125:409-418
55. Gupta PK, Charan VD, Saxena R. Spectrum of Von Willebrand disease and inherited platelet function disorders amongst Indian bleeders. Ann Hematol 2007;86:403-407
56. Hayward CPM. Inherited platelet disorders. Curr Opin Hematol 2003;10:362-368
57. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744
58. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CPM. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North America Specialized Coagulation Laboratory Association. Thromb Haemost 2005;93:549-553
59. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929
60. Platelet aggregation: part II. Some results from a new method of study. J Clin Pathol 1962;15:452-455
61. Michelson AD, Frelinger AL III, Furman MI. Current options in platelet function testing. Am J Cardiol 2006;98:4N-10N
62. Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005;123:172-183
63. Breddin HK. Can platelet aggregometry be standardized? Platelets 2005;16:151-158
64. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243-1252
65. Agren A, Wiman B, Stiller V, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006;4:201-208
66. Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis 2007;18:657-660
67. Parkin JD, Smith IL, O'Neill AI, Ibrahim KMA, Butcher LA. Mild bleeding disorders. A clinical and laboratory study. Med J Aust 1992;156:614-617
68. Wuillemin WA, Gasser KM, Zeerleder SS, et al. Evaluation of a platelet function analyzer (PFA-100®) in patients with a bleeding tendency. Swiss Med Wkly 2002;132:443-448
69. Sandoval C, Dong S, Visintainer P, et al. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol 2002;24:47-49
70. Gerrard JM, Duta E, Nosek-Cenkowska B, Singhroy S, Cheang M, Kobrinsky NL. A role for prostacyclin in bruising symptomatology. Pediatrics 1992;90:33-36
71. Simon DI, Stamler JS, Loh E, Loscalzo J, Francis SA, Creager MA. Effects of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995;26:339-342
72. Ubatuba FB, Moncada S, Vane JR. The effect of prostacyclin (PGI2) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb Haemost 1979;41:425-435
73. Brouwer JL, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 2006;145:807-815
74. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Washington, DC: Hematology, American Society of Hematology, Educational Program; 2005:1-12
75. Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006;108:1903-1910
76. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004;104:3943-3948
77. Panes O, Matus V, Sáez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood 2007;109:5242-5250